×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen at AHA Scientific Sessions 2013

Amgen will present the results from three Phase 2 studies of AMG 145 at the American Heart Association (AHA) Scientific Sessions 2013, taking place in Dallas November 16-20, 2013.

If you are at AHA, stop by Amgen's booth #720 to learn more.

Follow Amgen on Twitter at http://twitter.com/amgen to receive news updates during AHA.


Nov. 19, 2013 Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Nov. 14, 2013 Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
Nov. 12, 2013 Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013